Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Summary

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Eligibility

Inclusion Criteria:

Signed informed consent and be able to follow up.

Exclusion Criteria:

Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.

Conditions2

Interventions2

Related trials

• 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients — Peking Union Medical College Hospital
• 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients — Peking Union Medical College Hospital
• A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma — Peking University First Hospital
• CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Hua Zhu
• CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Peking University Cancer Hospital & Institute
• Lung Nodule Detection Using Ultra-long FOV PET/CT — University Medical Center Groningen
• Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma — Peking University Cancer Hospital & Institute
• PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors — Hua Zhu

Browse More Trials